Gabriele Grassi obtained a degree in Medicine and Surgery from the University of Trieste. He achieved his PhD at the International Center for Genetic Engineering and Biotechnology (ICGEB) in Trieste. He was then a Visiting Fellow at the National Institute of Health (Human Genetic Branch) Bethesda, Maryland, USA (1995–1997), and subsequently was an assistant in the Department of Molecular Pathology of the University of Tuebingen, Germany (1997–2003). His research interests focus on the development of nucleic-acid-based drugs (NABDs), such as miRNA, siRNA, and aptamers with therapeutic properties mainly against cancer. His research interest is also focused on the identification of delivery systems for NABDs. His group also works on the identification of the molecular mechanisms of various drugs for clinical use as well as the development of new diagnostic/monitoring tests for cancerous and non-cancerous pathologies. He has published 135 articles in international scientific journals and is the author of two patents on siRNA and aptamers, as well as a patent on a new method for evaluating lung function. He is also a member of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology. He is on the Editorial Board of the World Journal of Gastroenterology, Current Medicinal Chemistry, and Pharmaceutics.